Prophylactic cholecystectomy is not mandatory in patients candidate to the resection for small intestine neuroendocrine neoplasms: a propensity score-matched and cost-minimization analysis

Carlo Ingaldi1,2,7 · Laura Alberici1,2,7 · Claudio Ricci1,2,7,8 · Davide Campana2,3,7 · Cristina Mosconi4,7 · Valentina Ambrosini5,6,7 · Giuseppe Lamberti2,6,7 · Lisa Manuzzi2,6,7 · Francesco Minni1,2,7 · Riccardo Casadei1,2,7

Received: 22 April 2021 / Accepted: 21 June 2021 / Published online: 5 July 2021 © The Author(s) 2021

Abstract
To evaluate two competitive strategies in patients undergoing resection of Small-intestine neuroendocrine neoplasms (Si-NEN): prophylactic cholecystectomy (PC) versus On-demand delayed (OC) cholecystectomy. None comparative studies are available. This is a retrospective study based on 247 Si-NENs candidates for the primary tumor resection. Patients were divided into two arms: PC and OC. Propensity score matching was performed, reporting the \( d \) value. The primary outcome was the rehospitalization rate for any cause. The secondary endpoints were: the rehospitalization rate for biliary stone disease (BSD), the mean number of rehospitalization (any cause and BSD), the complication rate (all and severe). A \( P \) value < 0.05 was considered significant, and the number needed to treat (NNT) < 10 was considered clinically relevant. Before matching, 52 (21.1%) were in the PC arm and 195 (78.9%) in the OC group. The two arms have a sub-optimal balance for age (\( d = 0.575 \)), symptoms (\( d = 0.661 \)), ENETS TNM stage (\( d = 0.661 \)). After matching, we included 52 patients in PC and 104 in OC one. The two groups are well balanced (all \( d \) values < 0.5). The rehospitalization rate was similar in the two groups (36% vs 31%; \( P = 0.594 \); NNT = 21). The rehospitalization rate for BSD was lower in the PC arm than OC one (0% vs 7%) without statistical significance (\( P = 0.096 \)) and relevance (NNT = 15). The mean number of readmission (any cause and BSD) and the complication rate (all and severe) were similar. PC was not mandatory in patients having Si-NEN and candidates to the resection of primary tumors.

Keywords Small intestinal endocrine neoplasm · Cost analysis · Somatostain analogues

Introduction
Biliary stone disease (BSD) is common in patients treated with somatostatin analogues (SSA) for Small-intestine neuroendocrine neoplasms (Si-NENs) [1–4]. For this reason, a recent multicentric cohort study suggested the prophylactic cholecystectomy in all patients’ candidates to the resection of the primary tumors. Nevertheless, both European Neuroendocrine Tumors Society (ENETS) [5] and North American Endocrine Tumors Society (NANETS) [6] guidelines

1 Division of Pancreatic Surgery, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15, Bologna, Italy
2 Department of Internal Medicine and Surgery (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy
3 Division of Oncology, Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15, Bologna, Italy
4 Division of Radiology, Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15, Bologna, Italy
5 Division of Nuclear Medicine, Azienda Ospedaliero-Universitaria Di Bologna, via Albertoni 15, Bologna, Italy
6 Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
7 Center of Excellence for the Diagnosis and Cure of Neuroendocrine Neoplasms Certified By the European Neuroendocrine Tumor Society (ENETS), Berlin, Germany
8 Pancreas Unit, S.Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
do not strongly recommend a prophylactic cholecystectomy during primary tumor resection. Uncertainty and contradictory positions are due to the absence of high quality and comparative studies. In the past 25 years, only a non-comparative study was published about this topic. Indeed, Norlen et al. [7] reported that the incidence of gallstone-related complications was higher than in the general population, and for this reason, they recommend prophylactic cholecystectomy. However, the authors did not perform any comparison between on-demand delayed versus prophylactic cholecystectomy.

Thus, our study aimed to fill this gap by comparing two different strategies: on-demand delayed cholecystectomy (OC) for symptomatic biliary stone disease versus prophylactic cholecystectomy (PC) during the primary tumor resection. A propensity score matching (PSM) analysis was planned to minimize the selection bias. The primary endpoint was the rate of rehospitalization after primary tumor resection in the two groups. The secondary endpoints were the following: the rate of rehospitalization for BSD, the mean number of rehospitalization for any cause and BSD, and the complication rate and severity, the mean difference in rehospitalization due to BSD and any cause. We also evaluated the economic consequences of the two different strategies performing a cost-minimization analysis (CMA).

Methods

Study design

A retrospective study was carried out using a prospectively maintained database of patients treated at our Center of Excellence to diagnose and cure NENs certified by the European Neuroendocrine Tumor Society (ENETS). The database included all patients observed from January 2000 to December 2019 with a diagnosis of Si-NENs. All patients at the first visit or follow-up signed a non-specific written consent for retrospective non-interventional studies. Data collection, analysis and results were obtained using the principles of the STROCSS guidelines [8]. The study’s inclusion criteria were the following: (1) patients with a diagnosis of Si-NEN; (2) resection of the primary tumor with or without concomitant cholecystectomy; (3) absence of a history of a biliary stone disease or cholecystectomy before Si-NEN diagnosis. The following data were extracted for the matching: sex, age, comorbidity, presence of symptoms, type of surgery (emergency or elective), ENETS TNM stage [9], WHO 2019 grading [10] of the primary tumor, type of resection (R0/1 vs R2), administration of SSA therapy, duration of follow-up. The following parameters were compared: (a) the rate and the mean number of rehospitalization after primary tumor resection, defined as any new hospital admission for any cause; (b) the rate and the mean number of rehospitalization for the BSD, including biliary colic, cholecystitis, biliary pancreatitis, choledocholithiasis, and cholangitis; (c) the complication rate and severity after surgery classified by Clavien–Dindo score (CD) [11]; (d) overall and specific costs (the costs related to the surgery of Si-NENs tumors, and the costs for all types and BSD of rehospitalizations).

The analysis was conducted using the intention to treat principle, including in the OC arm, all patients with and without BSD or need of cholecystectomy. For the OC arm, the complication rate included the sum of events that occurred in both procedures.

Statistical analysis

All parameters were reported as frequencies and percentage, median and interquartile range (IQR) or mean and standard deviation (SD). The PSM was performed using logistic regression. The two groups were matched for the following parameters: sex, age, comorbidity, presence of symptoms, type of surgery, ENETS TNM stage, WHO 2019 grading of the primary tumor, type of resection, SSA-therapy, and duration of follow-up. The PSM method is closest to the neighborhood method having a caliper width of 0.20 pooled standard, and the matching was created with a 2:1 ratio.

Standardized mean difference (d value) was used to assess the balance between the two groups. A d value < 0.2 indicates a small difference between the two groups, identifying an excellent balance. A d value between 0.2 and 0.5 shows a medium difference, implying a good balance. A d value between 0.5 and 0.8 shows a high difference, implying a suboptimal balance. A d value > 0.8 resulted in a remarkable difference, suggesting a poor balance between the two groups. [12] The outcomes were also reported describing the number needed to treat (NNT) in adopting PC strategy instead of OC. The NNT was reported with a confidence interval of 95%. A negative value of NNT or within 95% CI indicates that the PC results in harmful [13]. When the NNT with 95% CI assumes positive value was interpreted as follows. Considering that the cholecystectomy was not a life-saving procedure, we considered that PC was very useful if NNT ≤ 1 [14]. The PC was considered moderately effective for NNT values between 1 and 10 and clinical useless for NNT > 10. The CMA analysis was conducted following the EVEREST guidelines [15]. The costs were assessed from the healthcare providers’ perspective and were extracted from the current payments within the Italian National Health, converted to the 2020-euro equivalent. [16]. A Monte Carlo probabilistic analysis was used to investigate the strategies’ economic impact, simulating different scenarios. In each scenario, we hypothesized different rehospitalization rates from 0 to 100%. The burden of biliary disease in total rehospitalization was maintained the same as our cohort. The number
of distribution samples of the Monte Carlo simulation was set at 3000 for each strategy arm, simulating a randomized clinical trial with 6000 patients for each cost scenario. The cost-analysis diagram model was plotted as follows: the blue square was the decision node; the green circles were the chance node; the red triangles were the terminal nodes. The cost distribution was obtained from our cohort for PC arm, no rehospitalization; PC arm, rehospitalization; OC arm, no rehospitalization; OC arm, rehospitalization. Statistical analysis was carried out using Fisher’s exact test, Student’s T test, and Pearson Chi-square test. Two-tailed P values inferior to 0.05 were considered statistically significant. Standardized mean difference (d value) was used to assess the two groups’ economic differences in the Montecarlo simulation. All statistical analyses were run with Statistical Package for Social Science (SPSS) version 21, STATA 14, and TreeAge Pro 2011.

Results

Patients included

Figure 1 shows the selection process. A total of 280 records were screened, but only 230 patients, who meet all inclusion criteria, were considered in the final analysis: 178 (77.4%) in the OC and 52 (22.6%) in the PC group. During the median follow-up of 61 (27–124) months, only 29 patients (16.3%) of the OC group developed lithiasis, and amongst these, only 16 patients (8.9%) underwent cholecystectomy due to symptomatic BSD. On the contrary, no choledocholithiasis or other biliary diseases were observed in the PC group. It should be noted that none of the cholecystectomies was performed in an emergency setting in the OC group.

Unmatched population

Clinical and demographic variables are reported in Supplementary Table 1. No significant or large differences were found between the two groups regarding sex, age, comorbidity, type of surgery, 2019 WHO grading, type of resection, or mean follow-up after primary tumor resection. Symptoms tumor-related were more frequently in OC than PC group (69.6% vs. 53.8%, P = 0.045). Comparing the two arm for the ENETS TNM stage distribution, we observed several patients in stage IV in the PC group (75% vs 42.7%; P < 0.001). Both groups showed a high percentage of patients treated with SSA therapy, with a statistically significant difference favoring the PC group (76.9% vs 60.0%, P = 0.033). Some of these differences suggesting a sub-optimal (symptoms with d = 0.373 and SSA therapy with d = 0.424) or poor balance (ENETS TNM stage; d = 0.694). The outcomes are reported in Supplementary Table 2. The rehospitalization rate for any cause was similar in the two groups (41.6% vs 30.8%; P = 0.197). Indeed, PC strategy was related in an NNT = 9, but it could result harmful in the worst scenario.
The re-hospitalization rate for BSD was lower in PC arm (8.9% vs. 0%; \( P = 0.026 \)). The PC strategy had an NNT = 11 (6–278), suggesting a useless effect in preventing BSD rehospitalization. The mean number of new rehospitalization was 1.1 ± 1.8 and 0.6 ± 1.2 (\( P = 0.083 \)) in the OC and PC groups, respectively. The rate and the severity of complications after primary tumor resection were similar with or without prophylactic cholecystectomy. No relevant clinical benefit was observed for PC strategy in surgical-related for all (NNT = 16; − 14 to 5, 95% CI) and severe complications (NNT = 67; − 25 to 14, 95% CI). The total costs were similar for the two groups (18,580 vs 19,684 euro for OC and PC, respectively; \( P = 0.282 \)). The primary tumor resection costs were higher in the PC than in OC (17,842 vs 14,758 Euro; \( P < 0.001 \)). The costs of rehospitalization for all-cause showed a tendency without statistical significance in favor of PC (1841 vs 3822 Euro; \( P = 0.054 \), in PC and OC, respectively). The rehospitalization costs for BSD were lower in PC (0 vs 370 Euro) without statistical significance (\( P = 0.071 \)).

**Matched population**

The demographic and clinical characteristics of the matched population are shown in Table 1. A total of 156 patients were included for the analysis, 104 for the OC group and 52 for the PC group. No sub-optimal or poor balancing was observed after PSM. Outcomes are reported in Table 2.

Regarding the primary endpoint, the rate of patients who experienced a new hospital admission were 36.5% vs 30.8% (difference +5.7%, \( P = 0.514 \)) in OC and PC groups, respectively. The PC strategy did not provide a clinically relevant advantage (NNT = 21; − 10 to 5, 95% CI). The rehospitalization rate for all-cause showed a tendency without statistical significance (\( P = 0.031 \)) and severe complication (NNT = 50; − 23 to 3). The re-hospitalization rate for BSD was lower in PC arm (8.9% vs. 0%; \( P = 0.026 \)). The PC strategy had an NNT = 11 (6–278), suggesting a useless effect in preventing BSD rehospitalization. The mean number of new rehospitalization was 1.1 ± 1.8 and 0.6 ± 1.2 (\( P = 0.083 \)) in the OC and PC groups, respectively. The rate and the severity of complications after primary tumor resection were similar with or without prophylactic cholecystectomy. No relevant clinical benefit was observed for PC strategy in surgical-related for all (NNT = 16; − 14 to 5, 95% CI) and severe complications (NNT = 67; − 25 to 14, 95% CI). The total costs were similar for the two groups (18,580 vs 19,684 euro for OC and PC, respectively; \( P = 0.282 \)). The primary tumor resection costs were higher in the PC than in OC (17,842 vs 14,758 Euro; \( P < 0.001 \)). The costs of rehospitalization for all-cause showed a tendency without statistical significance in favor of PC (1841 vs 3822 Euro; \( P = 0.054 \), in PC and OC, respectively). The rehospitalization costs for BSD were lower in PC (0 vs 370 Euro) without statistical significance (\( P = 0.071 \)).

**Table 1** Demographic, clinical characteristics of the matched population of patient resected for Si-NEN

| Factors | N (%) or Median (IQR) | \( P \) value | \( d \) value |
|---------|----------------------|-------------|-------------|
| Sex     |                      |             |             |
| Male    | 66 (63.5)            | 29 (55.8)   | 0.387       |
| Female  | 38 (36.5)            | 23 (44.2)   | 0.177       |
| Age (years) | 50 (58) – 60 (65) | 55 (55–70) | 0.010       |
| Comorbidity | No                 | 16 (30.8)   | 0.571       |
| Symptoms | No                  | 24 (46.1)   | 0.289       |
| Type of surgery | Elective     | 44 (84.6)   | 0.519       |
| ENETS TNM stage | I               | 0           | 0.930       |
| SSA therapy | No               | 12 (23.1)   | 0.350       |
| SSA therapy | Yes              | 10 (20.0)   | 0.216       |
| 2019 WHO grading | G1              | 41 (78.8)   | 0.255       |
| Type of resection | R0/1       | 29 (55.8)   | 0.396       |
| Follow-up (months) | 54 (26–124) | 71 (33–122) | 0.873       |

\( N \) number, IQR interquartile range, OC on-demand delayed cholecystectomy, PC upfront cholecystectomy, ENETS European Neuro-Endocrine Tumors Society, TNM tumor nodes metastasis, SSA somatostatin analogues, WHO World Health Organization, R0 radical resection with no microscopic residual of disease, R1 radical resection with a macroscopical residual of disease, R2 resection with a macroscopical residual of disease, Si-NEN small intestine neuroendocrine neoplasm without statistical significance in favor of PC (1841 vs 3676 Euro; \( P = 0.101 \), in PC and OC, respectively). The rehospitalization costs for BSD were lower in PC (0 vs 275 Euro) without statistical significance (\( P = 0.108 \)).

**CMA analysis**

The CMA analysis was reported in Table 3 and plotted in Figs. 2, 3. The Montecarlo simulation suggested that OC was the most expensive strategy in a setting with a high risk of rehospitalization (> 50%). The difference was large in very high-risk setting (99% to 90%, +2321 Euro, \( d \) value = 1.265).
The difference was medium ($d$ value = 0.211) for overall hospitalization rate equal to 80% and small for value < 80%. On the contrary, the OC approach’s costs were lower when the risk of rehospitalization was inferior to 50%. In a scenario with a rehospitalization rate similar to our cohort (40%), the OC approach permits us to gain near 1542 Euro for each patient managed with a medium difference ($d$ value = 0.351).

For rehospitalization rate inferior to 10% (low-risk setting), the OC was the less expensive strategy with a remarkable difference with PC in terms of overall costs (> 3429 Euro; $d$ value > 0.800). Figure 3 showed that the OC strategy was less expensive than the PC one, only when the BSD weighed the overall rehospitalization burden. In other words, in a setting where the rehospitalization rate was high, a PC strategy did not minimize the costs.

**Discussion**

The present study suggested that, in patients having Si-NENs, the PC is not mandatory with the primary tumor resection. Indeed, the OC had similar clinical results to the PC strategy with some economic advantages. This evidence is sustained by a comparative study in a large retrospective ENETS cohort for the first time. Indeed, we retrospectively analyzed our experience, dividing the patients into two groups representing the two competitive strategies: prophylactic cholecystectomy in “all patients” versus an “on-demand delayed cholecystectomy” only in patients with symptomatic BSD. It should be noted that the OC strategy was the same routinely used in the general population in which the cholecystectomy was performed when the BSD-related symptoms appeared [17]. Some methodological and statistical precautions have been taken to overcome the selection bias due to retrospective design. Firstly, the intention to treat principle was adopted, including in the OC arm, all patients with and without cholecystectomy during the follow-up. Secondly, we used the PSM analysis to minimize the difference between the two groups due to retrospective design and bias selection. Thirdly, the results were described using the NNT to report the clinical impact of the two strategies. Fourthly, the cost-minimization analysis was planned to consider the economic aspects.

### Table 2 Post-operative characteristics of the matched population of patient resected for Si-NEN

| Outcomes                                      | OC (104) | PC (52) | $P$ value | NNT (PC vs. OC) |
|-----------------------------------------------|---------|--------|----------|-----------------|
| Hospital re-hospitalization for any cause     |         |        |          |                 |
| No                                            | 66 (63.5) | 36 (69.2) | 0.593  | 18 (– 10^4 to 5) |
| Yes                                           | 38 (36.5) | 16 (30.8) |       |                 |
| Hospital re-hospitalization for BSD           |         |        |          |                 |
| No                                            | 97 (93.3) | 52 (100) | 0.096  | 15 (– 100^4 to 8) |
| Yes                                           | 7 (6.7) | 0 (0) |       |                 |
| Number of re-hospitalization for any cause (mean; SD) | 1.1 (1.9) | 0.6 (1.2) | 0.158 | - |
| Number of re-hospitalization for BSD (mean; SD)| 0.1 (0.5) | 0 | 0.104 | - |
| Complications (C–D)                           |         |        |          |                 |
| No                                            | 79 (75.9) | 37 (71.1) | 0.297  | 21 (– 5^4 to 10)* |
| 1                                             | 7 (6.7) | 1 (1.9) |       |                 |
| 2                                             | 14 (13.5) | 13 (25.0) |       |                 |
| 3                                             | 3 (2.9) | 1 (1.9) |       |                 |
| 4                                             | 1 (0.9) | 0 |       |                 |
| Severe complications (C–D ≥ 3)                |         |        | 0.665  | 50 (– 25^4 to 13) |
| No                                            | 100 (96.1) | 51 (98.1) |       |                 |
| Yes                                           | 4 (3.9) | 1 (1.9) |       |                 |
| Total cost (mean; SD; Euro)                   | 18,434 (7419) | 19,684 (4401) | 0.264 | – |
| Cost due to primary surgery (mean; SD; Euro)  | 14,758 (0) | 17,842 (380) | <0.001 | – |
| Total cost for all type of re-hospitalization (mean; SD; Euro) | 3676 (7419) | 1841 (4357) | 0.101 | – |
| Total cost for BSD re-hospitalization (mean; SD; Euro) | 275 (1229) | 0 | 0.108 | – |

N number, SD Standard deviation, OC on-demand delayed cholecystectomy, PC prophylactic cholecystectomy, NNT number needed to treat, BSD Biliary stone disease, C–D Clavien–Dindo classification

*Not computable

*The strategy resulted in a harm
The first interesting observation was that the overall rehospitalization rate was similar in both arms (36% vs 31%, OC, and PC, respectively). Thus, the PC strategy’s clinical advantages are marginal, avoiding only one rehospitalization every 18 cholecystectomies performed. Moreover, this advantage disappeared in the worst scenario.
because the NNT assumes negative values within the 95% CI. Considering only the readmission for BSD, we observed a difference in favor of the PC arm (7% vs 0%) with a statistical trend. Nevertheless, the PC strategy’s impact remained clinically not relevant, avoiding only one readmission every 15 cholecystectomies performed. Finally, the complication rate and the severity related to the two strategies were very similar. These results suggested that BSD’s weight in the mean rehospitalization rate of Si-NENs patients was very low. In other words, in most of the patient candidate for Si-NENs resection, a PC was useless because the BSD disease will represent a marginal reason for the rehospitalization. Thus, the OC and PC strategies were similarly efficacious and safe. This datum did not surprise because, as previously reported by Brighi et al. [1], the BSD was mainly related to SSA therapy. In our series, nearly one-third of patients did not receive SSA therapy because it was unnecessary during the follow-up. These patients can be considered “not more at risk” to the general population for BSD at the time of surgery. Moreover, Brighi et al. [1] suggested that only 27% of patients receiving SSA developed a BSD, further reducing the quote of patients “at-risk” for BSD at the time of surgery.

In other words, the PC strategy could be useful only for a minority of the patients. A CMA evaluation seems suitable in this setting because the two strategies are very similar in efficacy and safety. The CMA should be useful in establishing the treatment less expensive for the health care system. We compared the total cost of OC and PC strategy, observing that the PC arm’s total costs were higher than OC ones (19,684 vs 18,434 Euro; \( P = 0.264 \)), but this difference was not statistically relevant. The reason for them was that the PC costs related to the surgery were higher than OC (14,758 vs 17,842 Euro; \( P < 0.001 \)). The Montecarlo simulation confirmed that, in a large population, the PC advantages are limited, and, in intermediate scenarios, this strategy could be more expensive than the OC one.

From an economic perspective, the PC strategy was useful only in patients with a high rehospitalization rate. In other words, if our patient had a high risk for rehospitalization (e.g., metastatic disease or palliative resection), then the PC could produce some advantages reducing the costs for the health care system. On the contrary, in patients with a low risk of rehospitalization (e.g., localized neoplasm or radical resection), the BSD’s economic weight, per se, was low in the overall costs, and PC strategy seems to be too expensive for the Health care system.

The current study has some significant limitations: the retrospective and single-center design and the long observation period, only partially mitigated by intention to treat analysis, PSM approach, and use of NNT. Another limitation was that the primary endpoint is time-depending. The median observation time was 61 months, and the externalization of the results could be partially limited. Nonetheless, the “OC strategy” did not impose never performing the cholecystectomy but operating the patients only when symptomatic, similarly to the general population. Finally, several surgeons were involved in the procedures. However, all surgeons have completed the learning curve for the cholecystectomy, and all procedures were performed in high-volume hepato-biliary-pancreatic referral center.

In conclusion, the present study compared, for the first time, two competitive strategies in patients affected by Si-NEN. The on-demand surgery can be considered non-inferior to the prophylactic cholecystectomy in these patients, even in those candidates to receive SSA. This approach could avoid several useless and expensive cholecystectomies. All these results should be confirmed in prospective, large, and multicentric studies.

Provenance and peer review not commissioned, externally peer-reviewed.
Supplementary Information  The online version contains supplementary material available at https://doi.org/10.1007/s13304-021-01123-2.

Funding  Open access funding provided by Alma Mater Studiorum - Università di Bologna within the CRUI-CARE Agreement. The authors did not receive funds or grant for the manuscript.

Declarations

Conflict of interest  The authors declare that they do not have conflict of interest.

Ethics approval  The study was approved by local ethical committee.

Informed consent  All participants provided informed consent prior to their participation.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Brighi N, Panzuto F, Modica R et al (2020) Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study. Oncologist 25:259–265
2. Brighi N, Lamberti G, Maggio I et al (2019) Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Dig Liver Dis 51:689–694
3. Trendle MC, Moertel CG, Kvols LK (1997) Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer 79:830–834
4. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME (2009) Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Aliment Pharmacol Ther 30:733–740
5. Niederle B, Pape UF, Costa F et al (2016) ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology 103(2):125–138
6. Howe JR, Cardona K, Fraker DL et al (2017) The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society. Pancreas 46(6):715–731
7. Norlén O, Hesselman O, Ståberg P et al (2010) Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg 34:1361–1367
8. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G, STROCSS Group (2019) The STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 72:156–165
9. Rindi G, Klöppel G, Couvelard A et al (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762
10. WHO (2019) Classification of digestive system tumors, 5th edn, WHO Classification of Tumours Editorial Board (Eds). IARC Press, Lyon, p 343
11. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213
12. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Erlbaum, Hillsdale
13. Norlén O, Hessman O, Stålberg P et al (2010) Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg 34:1361–1367
14. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G, STROCSS Group (2019) The STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 72:156–165
15. Brighi N, Panzuto F, Modica R et al (2020) Biliary stone disease in patients with neuroendocrine tumors treated with somatostatin analogs: a multicenter study. Oncologist 25:259–265
16. Siegel JE, Weinstein MC, Russell LB et al (1996) Recommendations for reporting cost-effectiveness analyzes. Panel on cost-effectiveness in health and medicine. JAMA 276:1339–1341
17. https://salute.regione.emilia-romagna.it/siseps/sanita/sdo/files/allegato_3_TARIFFE_DRG.xls. Accessed Oct 2020
18. Tazuma S, Unno M, Igarashi Y et al (2017) Evidence-based clinical practice guidelines for cholelithiasis 2016. J Gastroenterol 52:276–300

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.